Oral Session 3-5D MDS: Clinical

[OS3-5D-3] MCV and reticulocyte count at diagnosis predict prognosis of MDS patients with low blast percentages

Hiroshi Kawabata^1,2, Kensuke Usuki³, Maki Shindo², Kaoru Tohyama⁴, Akira Matsuda⁵, Kayano Araseki⁶, Tomoko Hata⁷, Takahiro Suzuki⁸, Hidekazu Kayano⁹, Kei Shimbo¹⁰, Shigeru Chiba¹¹, Takayuki Ishikawa¹², Toshiyuki Kitano¹³, Masaharu Nohgawa¹⁴, Yasushi Miyazaki⁷, Mineo Kurokawa¹⁵, Shunya Arai¹⁵, Kinuko Mitani¹⁶, Akifumi Takaori-Kondo² (1.Dept. Hematol/Immunol, Kanazawa Medical Univ. Uchinada, Ishikawa-ken, Japan, 2.Dept. Hematol/Oncol, Kyoto Univ. Kyoto, Japan, 3.Dept. Hematol, NTT Medical Center Tokyo, Tokyo, Japan, 4.Dept. Laboratory Medicine, Kawasaki Medical School, Okayama, Japan, 5.Dept. Hemato-Oncol, International Medical Center, Saitama Medical Univ, Hidaka, Japan, 6.Div. Hematol, Saitama Medical Univ, Moroyama, Saitama, Japan, 7.Dept. Hematol, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan, 8.Dept. Hematol, Kitasato Univ. School of Med, Sagamihara, Kanagawa, Japan, 9.School of Medical Technol, Saitama Medical Univ, Hidaka, Saitama, Japan, 10.Clinical Lab Center, Dokkyo Medical Univ. Hospital, Mibu, Tochigi, Japan, 11.Dept. Hematol, Univ. Tsukuba, Ibaraki, Japan, 12.Dept. Hematol, Kobe City Medical Center General Hospital, Kobe, Japan, 13.Dept. Hematol, Medical Research Institute Kitano Hospital, Osaka, Japan., 14.Dept. Hematol, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan, 15.Dept. Hematol/Oncol, The University of Tokyo, Tokyo, Japan, 16.Dept. Hematol/Oncol, Dokkyo Medical Univ School of Med, Mibu, Japan)